Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients

被引:14
作者
Zhang, Yuhan [1 ,2 ,3 ,4 ,5 ]
Wang, Shuaibing [6 ]
Yang, Beibei [1 ,2 ,3 ,4 ,5 ]
Lu, Su [1 ,2 ,3 ,4 ,5 ]
Du, Yiyi [1 ,2 ,3 ,4 ,5 ]
Liu, Hong [1 ,2 ,3 ,4 ,5 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Canc 2, Tianjin, Peoples R China
[2] Natl Clin Res Ctr Canc, Tianjin, Peoples R China
[3] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[4] Tianjin Med Univ, Minist Educ, Tianjins Clin Res Ctr Canc, Tianjin 300060, Peoples R China
[5] Tianjin Med Univ, Minist Educ, Key Lab Breast Canc Prevent & Therapy, Tianjin 300060, Peoples R China
[6] China Natl Petr Corp, Cent Hosp, Oncol Dept, Langfang 065000, Peoples R China
关键词
Immunotherapy; triple-negative breast cancer; cytokine-induced killer cell; prognosis; disease-free survival; overall survival; CIK CELLS; PHASE-II; T-CELLS; CHEMOTHERAPY; SURVIVAL; THERAPY; IDENTIFICATION; EXPRESSION; EFFICACY; FEATURES;
D O I
10.20892/j.issn.2095-3941.2018.0378
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To examine the efficacy and safety of a sequential combination of chemotherapy and autologous cytokine-induced killer (CIK) cell treatment in triple-negative breast cancer (TNBC) patients. Methods: A total of 294 post-surgery TNBC patients participated in the research from January 1, 2009 to January 1, 2015. After adjuvant chemotherapy, autologous CIK cells were introduced in 147 cases (CIK group), while adjuvant chemotherapy alone was used to treat the remaining 147 cases (control group). The major endpoints of the investigation were the disease-free survival (DFS) and overall survival (OS). Additionally, the side effects of the treatment were evaluated. Results: In the CIK group, the DFS and OS intervals of the patients were significantly longer than those of the control group (DFS: P = 0.047; OS: P = 0.007). The multivariate analysis demonstrated that the TNM (tumor-node-metastasis) stage and adjuvant CIK treatment were independent prognostic factors for both DFS [hazard ratio (HR) = 0.520, 95% confidence interval (CI):0.2710.998, P = 0.049; HR = 1.449, 95% CI:1.118-1.877, P = 0.005, respectively] and OS (HR=0.414, 95% CI:0.190-0.903, P = 0.027; HR = 1.581, 95% CI:1.204-2.077, P = 0.001, respectively) in patients with TNBC. Additionally, longer DFS and OS intervals were associated with increased number of CIK treatment cycles (DFS: P = 0.020; OS: P = 0.040). The majority of the patients who benefitted from CIK cell therapy were relatively early-stage TNBC patients The side effects of CIK treatment were. Conclusion: Chemotherapy in combination with adjuvant CIK could be used to lower the relapse and metastasis rate, thus effectively extending the survival time of TNBC patients, especially those at the early stages.
引用
收藏
页码:350 / +
页数:19
相关论文
共 43 条
  • [1] PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
    Ali, H. R.
    Glont, S. -E.
    Blows, F. M.
    Provenzano, E.
    Dawson, S. -J.
    Liu, B.
    Hiller, L.
    Dunn, J.
    Poole, C. J.
    Bowden, S.
    Earl, H. M.
    Pharoah, P. D. P.
    Caldas, C.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (07) : 1488 - 1493
  • [2] Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients
    Andersen, Mads Hald
    Sorensen, Rikke Baek
    Brimnes, Marie K.
    Svane, Inge Marie
    Becker, Juergen C.
    Straten, Per Thor
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (08) : 2245 - 2256
  • [3] Role of Local Radiation Therapy in Cancer Immunotherapy
    Demaria, Sandra
    Golden, Encouse B.
    Formenti, Silvia C.
    [J]. JAMA ONCOLOGY, 2015, 1 (09) : 1325 - 1332
  • [4] Triple-negative breast cancer: Clinical features and patterns of recurrence
    Dent, Rebecca
    Trudeau, Maureen
    Pritchard, Kathleen I.
    Hanna, Wedad M.
    Kahn, Harriet K.
    Sawka, Carol A.
    Lickley, Lavina A.
    Rawlinson, Ellen
    Sun, Ping
    Narod, Steven A.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4429 - 4434
  • [5] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [6] Association of Antigen-Specific T-cell Responses with Antigen Expression and Immunoparalysis in Multiple Myeloma
    Fichtner, Sabrina
    Hose, Dirk
    Engelhardt, Melanie
    Meissner, Tobias
    Neuber, Brigitte
    Krasniqi, Fatime
    Raab, Marc
    Schoenland, Stefan
    Ho, Anthony D.
    Goldschmidt, Hartmut
    Hundemer, Michael
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1712 - 1721
  • [7] Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features
    Gammaitoni, Loretta
    Giraudo, Lidia
    Leuci, Valeria
    Todorovic, Maja
    Mesiano, Giulia
    Picciotto, Franco
    Pisacane, Alberto
    Zaccagna, Alessandro
    Volpe, Maria Giuseppa
    Gallo, Susanna
    Caravelli, Daniela
    Giacone, Elena
    Venesio, Tiziana
    Balsamo, Antonella
    Pignochino, Ymera
    Grignani, Giovanni
    Carnevale-Schianca, Fabrizio
    Aglietta, Massimo
    Sangiolo, Dario
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (16) : 4347 - 4358
  • [8] Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer
    Haffty, Bruce G.
    Yang, Qifeng
    Reiss, Michael
    Kearney, Thomas
    Higgins, Susan A.
    Weidhaas, Joanne
    Harris, Lyndsay
    Hait, Willam
    Toppmeyer, Deborah
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (36) : 5652 - 5657
  • [9] Hallmarks of Cancer: The Next Generation
    Hanahan, Douglas
    Weinberg, Robert A.
    [J]. CELL, 2011, 144 (05) : 646 - 674
  • [10] Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)
    Hontscha, C.
    Borck, Y.
    Zhou, H.
    Messmer, D.
    Schmidt-Wolf, I. G. H.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (02) : 305 - 310